NL
DE
Khondrion (a spin-off of the Radboudumc), a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces the publication of new research in PLOS ONE. They examined the in vivo active metabolite of sonlicromanol, as a selective inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1)-mediated PGE2 synthesis in prostate cancer stem cells and its potential as a novel treatment approach for prostate cancer and other cancers with high mPGES-1 expression.
Sonlicromanol (KH176) is Khondrion’s wholly-owned investigational lead asset, currently in phase IIb development as a potentially disease-modifying treatment for mitochondrial disease. The company has previously demonstrated the ability of sonlicromanol’s active metabolite to selectively inhibit mPGES-1, a key enzyme involved in the production of prostaglandin E2. This prostaglandin, known to induce and propagate the inflammation response, was found in significantly increased levels in cells derived from mitochondrial disease patients. Importantly, the aggressiveness of cancers, like prostate cancer, has also been found in independent studies to be associated with elevated expression of mPGES-1.
The new research, authored by Khondrion, details the effects of selective mPGES-1 targeting by sonlicromanol’s active metabolite, and examines its potential to decrease the aggressiveness of prostate cancer by inhibiting mPGES-1 expression.
The research team found that inhibition of mPGES-1 by sonlicromanol’s metabolite was able to considerably reduce spheroid growth in the human prostate cancer cell line DU145, potentially offering a novel approach in treating prostate cancer and other malignancies with high expression of mPGES-1. Sonlicromanol’s active metabolite was found to reduce the constitutively high mPGES-1 levels. The growth of spheroids in a physiological relevant 3D environment for tumour cells was reduced and the prostate cancer stem cell population was selectively decreased. These findings are of particular interest as they further strengthen earlier research indicating the potential of sonlicromanol as a treatment for patients with high mPGES-1 expression and signal its potential as an anti-tumour drug, based on its ability to decrease the size of cancer stem cell-formed spheroids.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Arnhem Nijmegen: top region in Health, High-Tech and Energy
10 February 2022 Projects in the Arnhem Nijmegen region can expect millions of extra euros in the coming years. This will be used for, amongst other things, the circular economy and pioneering applications in the fields of Health, High-tech and Energy. read more
Micro-Cosmos helps patient unwind during hospitalization
10 February 2022 Nijmegen-based Micro-Cosmos is a start-up that makes retractable hoods to speed up the recovery of hospitalized patients. read more
LUMO Labs and Oost NL invest in Aiosyn Investment accelerates development of artificial intelligence platform to improve diagnostics
7 February 2022 Aiosyn, a spin-off from Radboudumc, has received an investment from LUMO Labs. Oost NL is a co-investor. read more
More variants TLR7 gene found in young healthy men with severe Covid-19 Screening and accelerated vaccination for TLR7 immunodeficiency
3 August 2021 Spanish-Dutch research has revealed two new mutations in the TLR7 gene in healthy young men who became seriously ill with severe Covid-19. read more
Newborn screening in sight through the discovery of novel disease biomarkers by new technique
8 July 2021 To identify new biomarkers that can be used in the newborn screening protocol, also known as the neonatal heel prick, Karlien Coene and colleagues joined forces with scientists at the Radboud University’s FELIX laser laboratory. They published their findings in The Journal of Clinical Investigation. read more
